Publication at Faculty of Medicine in Hradec Králové |
2014
Abstract
Aclidinium bromide is a new bronchodilator drug from the group of anticholinergics intended for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The ACCORD and ATTAIN trials have confirmed that it is very effective in improving pulmonary functions and quality of life, and reduces symptoms, mainly those occurring at night and early in the morning.
Other studies have found that its efficacy was fully comparable with tiotropium, the most extensively used anticholinergic. In our market, aclidinium bromide, administered twice daily in the dose 400 µg, is distributed as Bretaris Genuair.